Drokov Mikhail Y, Davydova Julia O, Kuzmina Larisa A, Galtseva Irina V, Kapranov Nikolay M, Vasilyeva Vera A, Dubnyak Darya S, Koroleva Olga M, Mikhalcova Ekaterina D, Popova Natalia N, Parovichnikova Elena N, Savchenko Valery G
Bone Marrow Transplant Department, National Research Center for Hematology, Moscow, Russian Federation; Flow Cytometry Laboratory, National Research Center for Hematology, Moscow, Russian Federation.
Flow Cytometry Laboratory, National Research Center for Hematology, Moscow, Russian Federation.
Leuk Res. 2017 Mar;54:25-29. doi: 10.1016/j.leukres.2017.01.014. Epub 2017 Jan 10.
Acute Graft-versus-host-disease (aGVHD), the major complication and one of the main causes of poor outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nowadays there are no widely accepted cell, plasma or another biomarker that can be used for aGVHD prediction. We hypothesized that a level of Granzyme B-positive T regulatory (GZMB-positive Treg) cells on day+30 after allo-HSCT could be the measure of immune response suppression and could predict aGVHD development after day +30. We applied a widespread and easy-to-perform method of multicolor flow cytometry to measure level of GZMB-positive Treg cells. Levels of GZMB-positive Tregs on day +30 after allo-HSCT were significantly higher in those patients who never developed aGVHD in comparison with the other group of patient with aGVHD after day +30 (p=0.0229). We conclude that the level of GZMB-positive Treg cells is a strong predictor of acute Graft-versus-host disease after day +30 after allo-HSCT.
急性移植物抗宿主病（aGVHD）是异基因造血干细胞移植（allo-HSCT）的主要并发症及导致不良预后的主要原因之一。目前尚无广泛认可的可用于预测aGVHD的细胞、血浆或其他生物标志物。我们推测，allo-HSCT后第30天的颗粒酶B阳性调节性T细胞（GZMB阳性Treg）水平可作为免疫反应抑制的指标，并可预测第30天后aGVHD的发生。我们采用了一种广泛且易于操作的多色流式细胞术方法来检测GZMB阳性Treg细胞水平。与第30天后发生aGVHD的另一组患者相比，allo-HSCT后第30天从未发生aGVHD的患者中GZMB阳性Tregs水平显著更高（p=0.0229）。我们得出结论，GZMB阳性Treg细胞水平是allo-HSCT后第30天急性移植物抗宿主病的有力预测指标。
